Does Bill Ackman Have a 'Hate-On for Allergan?

The video discusses the business dynamics between Allergan, Valiant, and Actavis, focusing on Allergan's preference for Actavis over Valiant due to concerns about R&D cuts. Bill Ackman's role in the potential acquisition by Valiant is highlighted, along with his alternative plan involving Zoetis. The video also explores the potential outcomes of these business deals and their implications for the companies involved.

Why does Allergan prefer Actavis over Valiant?

• Valiant is a generic company.

• Actavis is known for slashing R&D.

• Valiant has a better reputation for R&D.

• Actavis offers a higher bid value.

What is Bill Ackman's Plan B if Valiant does not acquire Allergan?

• To get Valiant to buy Zoetis.

• To acquire another animal health company.

• To sell his stake in Zoetis.

• To merge Zoetis with Actavis.

What is a key reason for Valiant's interest in Zoetis?

• Zoetis has a large market share in Botox.

• Zoetis is a leader in animal health.

• Zoetis is a cash-generating business.

• Zoetis has a strong R&D reputation.

What is the potential benefit for Valiant in acquiring Allergan?

• Stronger brand recognition.

• Better fit with animal health products.

• Higher cash generation synergy.

• Lower debt requirement compared to Zoetis.

What is a financial consideration for Valiant when choosing between Allergan and Zoetis?

• Allergan has a higher market value than Zoetis.

• Zoetis requires more debt than Allergan.

• Zoetis offers better cash generation than Allergan.

• Allergan requires more debt than Zoetis.